ArticlePloS one2013

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.

Tandakha N Dieye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.